U.S. FDA's Strategic Priorities - 2014 and Beyond - Webinar by GlobalCompliancePanel

GlobalCompliancePanel, Online Training, 161 Mission Falls Lane, Suite 216, Fremont, CA 94539, USA
2013-12-11

Overview: This webinar will examine the FDA's recently instituted annual "Strategic Priorities" initiative, with emphasis on 2014. Such a review will focus on the broad range of issues a company's senior management and QA/RA need to consider in their annual Management Review of their existing quality management system. 

This review takes on added urgency as a result of the stated intent of the Agency to get tougher across the board in its expectations for the medical industry and what the FDA and industry need to do internally. An additional review of recent information from the Agency, other goals of the Agency that have already been translated into action in the past year will provide direction in areas of concern and what to expect in the future. This will be performed by a review of applicable FDA "Strategic Priorities" areas for required review or related industry problem areas. Major 510(k) changes already proposed will be discussed. The result will be a basis for such a management review and a listing of likely milestones and tasks. Anticipation and addressing of weak spots proactively will further prove a company is "in control", assist in timely review of submissions to the Agency, and in any remediation efforts. 

Why Should You Attend: Each year companies are to perform a complete review of their quality management system and its ability to meet the current GMP's. The FDA has added a "Strategic Priorities" initiative that can assist companies to proactively address areas of GMP concern. There is a major shift in the emphasis of the U.S. FDA cGMP compliance audits, clinical trial expectations, product submissions and company response requirements.

In short, all regulatory areas are under evaluation by the FDA, and need to be revisited by a company's QA/RA and its senior management. There is "no business as usual". This change in focus has a major impact on interpretation of individual compliance objectives, cGMP objectives, and measurements of success. On-going negative publicity on pharmaceuticals, devices, as well as events in unrelated industries show many senior executives just don't get it, and have put pressure on the Agency to "get tough on compliance / enforcement". This webinar will trigger such a response by an examination / review of FDA's "must-have's" for corporate CGMP compliance. 

Areas Covered in the Session:

Mandated Areas for Annual Reviews
The FDA's "Strategic Priorities" for 2014 and Beyond
Tougher Regulatory Science - What "Better Science" Really Means
Device, Pharmaceutical and Biological Issues
General CGMP Issues - Strengthened Compliance
Major Pending 510(k) Changes
FDA's Life Cycle View Requirements
Safety / Integrity of Global Supply Chain
Heightened Supplier Issues
FDA Clearance / Approval Only the Beginning - Product "Lifecycles"

Who Will Benefit:

Senior management in Drugs, Devices, Biologics, Dietary Supplements
QA
RA
R&D
Engineering
Production
Operations
Consultants